Efficacy of Simbrinza and Rocklatan vs Cosopt and Latanoprost

Part of paid clinical trials in Springfield, Illinois.

Sponsor
Prairie Eye Center
Study ID
NCT06883123
Phase
PHASE4
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Accepted

Interventions

  • Simbrinza 0.2%-1% Ophthalmic Suspension — DRUG
    brinzolamide and brimonidine tartrate
  • Rocklatan 0.02%-0.005% Ophthalmic Solution — DRUG
    netarsudil and latanoprost
  • Cosopt PF 2%-0.5% Ophthalmic Solution — DRUG
    dorzolamide hydrochloride and timolol maleate
  • Latanoprost 0.005% Ophthalmic Solution — DRUG
    Latanoprost

Study Details

A randomized, multi-site, parallel-group, prospective study of patients who are adults with a diagnosis of mild to moderate open-angle glaucoma (OAG), currently on an on-label use of combination topical medication of Cosopt and Latanoprost for a minimum of 1 month.

Key Dates

Start date
May 14, 2025
Status verified
May 2025
Primary completion
Apr 1, 2026
Completion
Apr 1, 2026

Study Design

Enrollment
70 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: Simbrinza and Rocklatan
    SIMBRINZA (brinzolamide and brimonidine tartrate) 1%/0.2% ROCKLATAN (netarsudil and latanoprost) 0.02%/0.005%
  • Active Comparator: Cosopt and Latanoprost
    COSOPT (dorzolamide hydrochloride and timolol maleate) 2%/0.5% Latanoprost 0.005%

Primary Outcome Measure

Decrease in mean diurnal IOP [ Time Frame: from baseline at week 8 ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Prairie Eye CenterSpringfieldIllinois62704
Jennifer Lyons
[email protected]
217-257-3102
Sanda Yeh, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Springfield, IL

By condition
Glaucoma
By specialty
Ophthalmology
By research site
Prairie Eye Center· Springfield, IL

Related Studies